Intellectual property estate now includes 25 issued patents for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs) SAN DIEGO , Feb. 5, 2018 /PRNewswire/ -- Biocept, Inc.
SAN DIEGO , March 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
SAN DIEGO , March 12, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release
Data highlights clinical proof-of-concept for monitoring metastatic testicular cancer using the Company's proprietary CTC assays, as well as validation of Biocept's high sensitivity circulating tumor DNA tests on Thermo Fisher QuantStudio™5 instrument SAN DIEGO , March 15, 2018 /PRNewswire/ --
SAN DIEGO , March 20, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the presentation of analytical
Collaboration plans to establish Biocept as Thermo Fisher Center of Excellence for liquid biopsy and to pursue commercial opportunities in both pharmaceutical and clinical markets SAN DIEGO , March 28, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
2017 revenues increased 57% due to higher reimbursement for Target Selector™ liquid biopsy tests and the impact of conversion to accrual-based revenue recognition Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , March 28, 2018 /PRNewswire/ -- Biocept, Inc.
Expands intellectual property position to 26 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers found in tissue, blood and other biological sources SAN DIEGO , March 29, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
Company to also co-host roundtable discussion SAN DIEGO , April 3, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with
Company to also co-host roundtable discussion SAN DIEGO , April 6, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with
